Company intelligence / Profile preview
Dyadic International, Inc.
Jupiter, FL, United Statesdyadic.com ↗
- Ownership
- Public · DYAI
- Development stage
- Preclinical
01
Overview
Dyadic has reported positive Phase I first-in-human data for a recombinant vaccine produced using their C1 platform. Their lead product DNAS1 is in NDA Preparation/In Review stage.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant proteinsVaccinesTherapeutic proteinsMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Top five pharmaceutical companyGlobal biopharmaceutical company
04
Financials
- Market cap
- $13.6M
- Total revenue
- $1.2M
- Enterprise value
- $15.6M
Beyond the preview
Go deeper on Dyadic International, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dyadic International, Inc..